Gm Advisory Group, Inc. Reata Pharmaceuticals Inc Transaction History

Gm Advisory Group, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$25.61 - $110.96 $63,103 - $273,405	-2,464 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$100.0 - $143.02 $55,000 - $78,661	550 Added 28.74%	2,464 $248,000
Q2 2021 Aug 16, 2021	BUY	$78.27 - $151.29 $149,808 - $289,569	1,914 New	1,914 $271,000
Q1 2021 May 13, 2021	SELL	$94.25 - $132.81 $345,803 - $487,279	-3,669 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$102.03 - $184.62 $48,974 - $88,617	480 Added 15.05%	3,669 $454,000
Q3 2020 Nov 12, 2020	BUY	$93.53 - $163.34 $13,655 - $23,847	146 Added 4.8%	3,189 $311,000
Q2 2020 Aug 13, 2020	BUY	$126.3 - $176.56 $30,690 - $42,904	243 Added 8.68%	3,043 $475,000
Q1 2020 May 13, 2020	BUY	$124.16 - $247.74 $347,648 - $693,672	2,800 New	2,800 $404,000

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Gm Advisory Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Gm Advisory Group, Inc. with notifications on news.